Is restless legs syndrome underrecognized? Current management.
Abstract
Restless legs syndrome (RLS) is a poorly understood sensory-motor neurological disorder whose prevalence in Caucasian populations ranges from 10% to 15%. The patient reports unpleasant sensations in the lower limbs with dysesthesia resulting in an urge to move the legs. The symptoms occur during periods of inactivity, increasing in the evening and at night. Moving the legs provides relief. In 80% of cases, polysomnography shows periodic leg movements during sleep. Patients with idiopathic RLS often report similar symptoms in family members. Secondary RLS may be due to medications, diabetes mellitus, renal failure, iron deficiency, neurological disorders, or rheumatoid arthritis. In secondary RLS, the management rests on treatment of the cause. Symptomatic treatment is warranted in patients with moderate-to-severe symptoms that adversely affect the quality of life. Dopaminergic agents are tried first. When they fail or induce adverse effects, weak opioids, benzodiazepines, anticonvulsants or, if needed, strong opioids, may be used.
Used In Evidence Reviews
Similar Papers
Sleep medicine · 2004
Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).
Neurology · 2004
Restless legs syndrome and pregnancy.
Movement disorders : official journal of the Movement Disorder Society · 2008
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice.
Nature reviews. Neurology · 2010
Restless legs syndrome: pathophysiology, clinical presentation and management.
Sleep medicine · 2014
Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).
Sleep medicine · 2016